{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:17:21Z","timestamp":1775060241388,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T00:00:00Z","timestamp":1313625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00277-011-1308-y","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T14:01:07Z","timestamp":1313589667000},"page":"391-397","source":"Crossref","is-referenced-by-count":26,"title":["Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors"],"prefix":"10.1007","volume":"91","author":[{"given":"Christian Johannes","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony Dick","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,18]]},"reference":[{"key":"1308_CR1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdn663","volume":"20","author":"A Ant\u00f3n","year":"2009","unstructured":"Ant\u00f3n A, Ruiz A, Segu\u00ed MA, Calvo L, Mu\u00f1oz M, Lao J, Sancho F, Fern\u00e1ndez L (2009) Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003\u201303 study. Ann Oncol 20:454\u2013459, Epub 2008 Dec 11","journal-title":"Ann Oncol"},{"key":"1308_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/annonc\/mdq317","volume":"22","author":"A Ant\u00f3n","year":"2010","unstructured":"Ant\u00f3n A, Ruiz A, Plazaola A, Calvo L, Segu\u00ed MA, Santaballa A, Mu\u00f1oz M, S\u00e1nchez P, Miguel A, Carrasco E, Lao J, Camps J, Alfaro J, Antol\u00edn S, C\u00e1mara MC (2010) Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003\u201303 study. Ann Oncol 22:74\u201379","journal-title":"Ann Oncol"},{"key":"1308_CR3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-B","volume":"24","author":"BR Baack","year":"1991","unstructured":"Baack BR, Burgdorf WH (1991) Chemotherapy-induced acral erythema. J Am Acad Dermatol 24:457\u2013461","journal-title":"J Am Acad Dermatol"},{"key":"1308_CR4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0190-9622(93)70187-X","volume":"29","author":"JS Beard","year":"1993","unstructured":"Beard JS, Smith KJ, Skelton HG (1993) Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. J Am Acad Dermatol 29:325\u2013330","journal-title":"J Am Acad Dermatol"},{"key":"1308_CR5","first-page":"496","volume":"91","author":"E Brusamolino","year":"2006","unstructured":"Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M, 4 (2006) Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 91:496\u2013502, Epub 2006 Mar 15","journal-title":"Haematologica"},{"issue":"4","key":"1308_CR6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244","journal-title":"J Clin Oncol"},{"key":"1308_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"1308_CR8","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","volume":"42","author":"RE Coleman","year":"2006","unstructured":"Coleman RE, Biganzoli L, Canney P et al (2006) A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 42:882\u2013887","journal-title":"Eur J Cancer"},{"issue":"3","key":"1308_CR9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","volume":"44","author":"F Nigris de","year":"2008","unstructured":"de Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C (2008) Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer 44(3):334\u2013340","journal-title":"Eur J Cancer"},{"issue":"7","key":"1308_CR10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"DA Gewirtz","year":"1999","unstructured":"Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727\u2013741","journal-title":"Biochem Pharmacol"},{"key":"1308_CR11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.leukres.2010.07.024","volume":"35","author":"E Gimeno","year":"2011","unstructured":"Gimeno E, S\u00e1nchez-Gonz\u00e1lez B, Alvarez-Larr\u00e1n A, Pedro C, Abella E, Com\u00edn J, Saumell S, Garc\u00eda-Pallarols F, G\u00f3mez M, Besses C, Salar A (2011) Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leuk Res 35:358\u2013362","journal-title":"Leuk Res"},{"issue":"1","key":"1308_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","volume":"94","author":"L Harris","year":"2002","unstructured":"Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, TLC D-99 Study Group (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94(1):25\u201336","journal-title":"Cancer"},{"issue":"2","key":"1308_CR13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00277-009-0796-5","volume":"89","author":"D Heintel","year":"2010","unstructured":"Heintel D, Skrabs C, Hauswirth A, Eigenberger K, Einberger C, Raderer M, Sperr WR, Kn\u00f6bl P, M\u00fcllauer L, Uffmann M, Dieckmann K, Gaiger A, J\u00e4ger U (2010) Nonpegylated liposomal doxorubicin is highly active in patients with B and T\/NK cell lymphomas with cardiac comorbidity or higher age. Ann Hematol 89(2):163\u2013169","journal-title":"Ann Hematol"},{"key":"1308_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","volume":"7","author":"RM Lang","year":"2006","unstructured":"Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W, 2 (2006) American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 7:79\u2013108","journal-title":"Eur J Echocardiogr"},{"key":"1308_CR15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","volume":"32","author":"EA Lefrak","year":"1973","unstructured":"Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32:302\u2013314","journal-title":"Cancer"},{"key":"1308_CR16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000081324","volume":"67","author":"D Lorusso","year":"2004","unstructured":"Lorusso D, Naldini A, Testa A, D'Agostino G, Scambia G, Ferrandina G (2004) Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology 67:243\u2013249","journal-title":"Oncology"},{"key":"1308_CR17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","volume":"1","author":"E Nagore","year":"2000","unstructured":"Nagore E, Insa A, Sanmartin O (2000) Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome. Incidence, recognition and management. Am J Clin Dermatol 1:225\u2013234","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1308_CR18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C (2004) CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440\u2013449","journal-title":"Ann Oncol"},{"issue":"3","key":"1308_CR19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0022-3565(24)36521-8","volume":"280","author":"MJ Parr","year":"1997","unstructured":"Parr MJ, Masin D, Cullis PR, Bally MB (1997) Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319\u20131327","journal-title":"J Pharmacol Exp Ther"},{"key":"1308_CR20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, L\u00f3pez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"issue":"2","key":"1308_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Tr\u00fcmper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105\u2013116","journal-title":"Lancet Oncol"},{"issue":"3","key":"1308_CR22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1634\/theoncologist.10-3-205","volume":"10","author":"PG Rose","year":"2005","unstructured":"Rose PG (2005) Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10(3):205\u2013214","journal-title":"Oncologist"},{"issue":"1","key":"1308_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.829","volume":"26","author":"A Rueda","year":"2008","unstructured":"Rueda A, Sabin P, Rif\u00e1 J, Llanos M, G\u00f3mez-Codina J, Lobo F, Garc\u00eda R, Herrero J, Provencio M, Jara C (2008) Grupo Oncol\u00f3gico para el Tratamiento y Estudio de los Linfomas (GOTEL) R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70\u00a0years: a multicentre, prospective study. Hematol Oncol 26(1):27\u201332","journal-title":"Hematol Oncol"},{"issue":"Suppl 2","key":"1308_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.8-suppl_2-17","volume":"8","author":"T Safra","year":"2003","unstructured":"Safra T (2003) Cardiac safety of liposomal anthracyclines. Oncologist 8(Suppl 2):17\u201324","journal-title":"Oncologist"},{"key":"1308_CR25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","volume":"61","author":"T Sim\u016fnek","year":"2009","unstructured":"Sim\u016fnek T, St\u00e9rba M, Popelov\u00e1 O, Adamcov\u00e1 M, Hrdina R, Gersl V, 1 (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154\u2013171","journal-title":"Pharmacol Rep"},{"issue":"4","key":"1308_CR26","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15(4):1318\u20131332","journal-title":"J Clin Oncol"},{"issue":"1","key":"1308_CR27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","volume":"86","author":"Z Symon","year":"1999","unstructured":"Symon Z, Peyser A, Tzemach D, Lyass E, Sucher E, Shezen E, Gabizon A (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86(1):72\u201378","journal-title":"Cancer"},{"key":"1308_CR28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pcad.2006.10.002","volume":"49","author":"G Takemura","year":"2007","unstructured":"Takemura G, Fujiwara H, 5 (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330\u2013352","journal-title":"Prog Cardiovasc Dis"},{"key":"1308_CR29","first-page":"1845","volume":"22","author":"N Tsavaris","year":"2002","unstructured":"Tsavaris N, Kosmas C, Vadiaka M, Giannouli S, Siakantaris MP, Vassilakopoulos T, Pangalis GA, 3 (2002) Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III\/IV) non-Hodgkin's lymphoma. Anticancer Res 22:1845\u20131848","journal-title":"Anticancer Res"},{"key":"1308_CR30","first-page":"CD005006","volume":"5","author":"EC Dalen van","year":"2010","unstructured":"van Dalen EC, Michiels EM, Caron HN, Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 5:CD005006","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1308_CR31","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710\u2013717","journal-title":"Ann Intern Med"},{"issue":"12","key":"1308_CR32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","volume":"24","author":"DN Waterhouse","year":"2001","unstructured":"Waterhouse DN, Tardi PG, Mayer LD, Bally MB (2001) A comparison of liposomal formulations of doxorubicin with drug administered in free form. Drug Saf 24(12):903\u2013920","journal-title":"Drug Saf"},{"issue":"25","key":"1308_CR33","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","volume":"109","author":"ET Yeh","year":"2004","unstructured":"Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25):3122\u20133131","journal-title":"Circulation"},{"issue":"10","key":"1308_CR34","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1080\/10428190600799946","volume":"47","author":"F Zaja","year":"2006","unstructured":"Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari AL, Fabbri A, Battista R, Cabras MG, Gallamini A, Fanin R (2006) CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 47(10):2174\u20132180","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1308-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-011-1308-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1308-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T21:40:56Z","timestamp":1741470056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1308-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,18]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1308-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,18]]}}}